Simcere Pharma (02096.HK) announced that the new insomnia drug, Sovecpa (Darliretide hydrochloride tablets), developed in collaboration with Idorsia, has been accepted for market application by the China National Medical Products Administration. In November 2022, the group obtained the exclusive right to develop and commercialize Darliretide hydrochloride in Greater China from Idorsia. Darliretide hydrochloride is the only DORA class of insomnia medication approved by the European Medicines Agency (EMA) to improve daytime function.
先聲藥業(02096.HK)失眠症藥物科唯可上市申請獲受理
Simcere Pharma (02096.HK) insomnia drug Keveyis's application for listing has been accepted.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.